Published in Muscle Nerve on April 01, 1999
Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest (2000) 1.91
Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex. J Clin Invest (2001) 1.41
Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy. J Immunol (2011) 0.98
Long-term miR-669a therapy alleviates chronic dilated cardiomyopathy in dystrophic mice. J Am Heart Assoc (2013) 0.87
Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies. Hum Mol Genet (2015) 0.84
β-Sarcoglycan gene transfer decreases fibrosis and restores force in LGMD2E mice. Gene Ther (2015) 0.83
Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E. Neurology (2015) 0.83
Muscle fatigue, nNOS and muscle fiber atrophy in limb girdle muscular dystrophy. Acta Myol (2014) 0.81
Magnetic resonance imaging assessment of cardiac dysfunction in δ-sarcoglycan null mice. Neuromuscul Disord (2010) 0.80
Occult left ventricular dysfunction diagnosed by myocardial performance index in patients with limb girdle muscle dystrophy: A case control study. Int J Angiol (2007) 0.77
Sarcoglycan, the heart, and skeletal muscles: new treatment, old drug? J Clin Invest (2001) 0.77
Mendelian forms of structural cardiovascular disease. Curr Cardiol Rep (2013) 0.75
Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E Mice. Mol Ther (2017) 0.75
A slowly progressive form of limb-girdle muscular dystrophy type 2C associated with founder mutation in the SGCG gene in Puerto Rican Hispanics. Mol Genet Genomic Med (2015) 0.75
MicroRNA based treatment of cardiomyopathy: not all dystrophies are created equal. J Am Heart Assoc (2013) 0.75
Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell (1987) 16.01
Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation (2001) 5.68
Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med (1994) 4.83
Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res (2001) 4.51
Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet (1998) 4.38
Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature (1989) 4.08
Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell (1988) 3.57
SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology (2010) 3.37
Immunoelectron microscopic localization of dystrophin in myofibres. Nature (1988) 3.37
Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol (2000) 3.34
Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet (2001) 3.12
MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts. Proc Natl Acad Sci U S A (1992) 2.82
Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet (1991) 2.79
The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature (1988) 2.75
Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med (1995) 2.75
Mutations in the integrin alpha7 gene cause congenital myopathy. Nat Genet (1998) 2.66
Correlating phenotype and genotype in the periodic paralyses. Neurology (2004) 2.55
Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nat Genet (1995) 2.53
Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology (2005) 2.53
MELAS: clinical features, biochemistry, and molecular genetics. Ann Neurol (1992) 2.48
Indian Agarwal megalencephalic leukodystrophy with cysts is caused by a common MLC1 mutation. Neurology (2004) 2.48
Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science (1973) 2.34
Fingerprint body myopathy, a newly recognized congenital muscle disease. Mayo Clin Proc (1972) 2.34
Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study. Neurology (2009) 2.33
Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol (2001) 2.29
The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23-q24. Hum Mol Genet (1994) 2.18
Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord (2009) 2.13
Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology (2006) 2.11
Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol (2000) 2.08
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology (2011) 2.06
Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. Biochem Biophys Res Commun (1995) 2.06
Hybrid test bench for evaluation of any device related to mechanical cardiac assistance. Int J Artif Organs (2005) 2.05
Hyperkalemic periodic paralysis and the adult muscle sodium channel alpha-subunit gene. Science (1990) 1.99
Familial skewed X inactivation: a molecular trait associated with high spontaneous-abortion rate maps to Xq28. Am J Hum Genet (1997) 1.99
Rett syndrome: confirmation of X-linked dominant inheritance, and localization of the gene to Xq28. Am J Hum Genet (1998) 1.98
A Met-to-Val mutation in the skeletal muscle Na+ channel alpha-subunit in hyperkalaemic periodic paralysis. Nature (1991) 1.92
Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology (2005) 1.90
Myotonic dystrophy: evidence for a possible dominant-negative RNA mutation. Hum Mol Genet (1995) 1.89
Normal myogenic cells from newborn mice restore normal histology to degenerating muscles of the mdx mouse. J Cell Biol (1990) 1.86
Mutations in the sarcoglycan genes in patients with myopathy. N Engl J Med (1997) 1.82
Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology (1989) 1.81
Type 1 fiber abnormalities in skeletal muscle of patients with hypertrophic and dilated cardiomyopathy: evidence of subclinical myogenic myopathy. J Am Coll Cardiol (1989) 1.76
Elevated basic fibroblast growth factor in the serum of patients with Duchenne muscular dystrophy. Ann Neurol (1994) 1.73
Cerebellar ataxia and coenzyme Q10 deficiency. Neurology (2003) 1.73
Genetic localization of a new locus for recessive familial spastic paraparesis to 15q13-15. Neurology (1999) 1.72
Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene. J Biol Chem (1994) 1.64
Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy: evidence for failure of dystrophin production in dystrophin-competent myonuclei. Neurology (1995) 1.62
IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol (1994) 1.62
Detecting differentially expressed genes in multiple tag sampling experiments: comparative evaluation of statistical tests. Hum Mol Genet (2001) 1.61
Identification of a chromosome 6-encoded dystrophin-related protein. J Biol Chem (1990) 1.60
The frequency of patients with dystrophin abnormalities in a limb-girdle patient population. Neurology (1991) 1.59
Gene expression profiling in postmortem Rett Syndrome brain: differential gene expression and patient classification. Neurobiol Dis (2001) 1.59
Primary adhalin deficiency as a cause of muscular dystrophy in patients with normal dystrophin. Ann Neurol (1995) 1.58
Retrospective study on PET-SPECT imaging in a large cohort of myotonic dystrophy type 1 patients. Neurol Sci (2010) 1.58
Genetic mapping and dominance of the amber suppressor, Su1 (supD), in Escherichia coli K-12. J Bacteriol (1970) 1.57
Familial effort polymorphic ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy map to chromosome 1q42-43. Am J Cardiol (2000) 1.57
Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy. J Exp Med (1996) 1.56
Roentgenographic skeletal injury patterns in parachute jumping. Am J Sports Med (1983) 1.55
Caveolin-3 in muscular dystrophy. Hum Mol Genet (1998) 1.55
Molecular findings in symptomatic and pre-symptomatic Alexander disease patients. Neurology (2002) 1.54
Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. Circulation (1996) 1.54
A computational reconstruction of the adult human heart transcriptional profile. J Mol Cell Cardiol (2000) 1.53
Monosomy of distal 4q does not cause facioscapulohumeral muscular dystrophy. J Med Genet (1996) 1.52
A comprehensive, high-resolution genomic transcript map of human skeletal muscle. Genome Res (1998) 1.51
A dystrophin missense mutation showing persistence of dystrophin and dystrophin-associated proteins yet a severe phenotype. Ann Neurol (1998) 1.48
Skewed X inactivation in a female MZ twin results in Duchenne muscular dystrophy. Am J Hum Genet (1990) 1.48
Prevention of atrial tachyarrhythmias after non-cardiac thoracic surgery by infusion of magnesium sulfate. Thorac Cardiovasc Surg (1996) 1.47
Phenotypic heterogeneity associated with the splicing mutation in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab (1996) 1.46
Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr Res (1995) 1.45
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
Laminin alpha2 muscular dystrophy: genotype/phenotype studies of 22 patients. Neurology (1998) 1.42
Dystrophin diagnosis: comparison of dystrophin abnormalities by immunofluorescence and immunoblot analyses. Proc Natl Acad Sci U S A (1989) 1.40
Evidence for a heterozygote advantage in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab (1997) 1.40
Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophy. Hum Mol Genet (1996) 1.39
A stop-codon mutation in the human mtDNA cytochrome c oxidase I gene disrupts the functional structure of complex IV. Am J Hum Genet (1999) 1.36
MeCP2 mutations in children with and without the phenotype of Rett syndrome. Neurology (2001) 1.36
Cardiac involvement in Becker muscular dystrophy. J Am Coll Cardiol (1993) 1.36